Introduction: These include the VOCs B.1.351/Beta and P.1/Gamma, which carry the spike variant N501Y that is also found in B.1.1.7/Alpha and a similar pair of mutations (K417N/T and E484K) that were each shown to reduce the binding affinity of antibodies from vaccine-derived or convalescent sera .
Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants.
Introduction: Among the SARS-CoV-2 variants of concern, Beta B.1.351 (RBD-K417N/E484K/N501Y) discovered in South Africa and Gamma P.1 (RBD-K417T/E484K/N501Y) discovered in Brazil have been demonstrated to have high potential to reduce the efficacy of some vaccines.
Discussion: The valuable information that K417 are essential for multiple prototype VH3-53/3-66 NAb recognition allows us to re-interpret the potential significance of the mutation K417N and K417T present in B.1.351 and P.1.
Emerging SARS-CoV-2 variants expand species tropism to murines.
Result: 1e-g), suggesting the K417N/T and E484K mutation in the RBD of these variants might further facilitate mouse adaptation in addition to the N501Y substitution.
Functional Effects of Receptor-Binding Domain Mutations of SARS-CoV-2 B.1.351 and P.1 Variants.
Result: The K417N ( Figure 4A ) and K417T mutants ( Figure 4B ) had no noticeable effect.
Result: The K417N:but not the K417T:appeared to be inhibited better than the wt.
Result: We observed a 1.9- and 1.5-fold reduction in the median inhibition of the E484K and N501Y RBD compared to the wt, while the substitutions in the 417 position had puzzlingly opposite effects with apparent 1.4- and 1.2-fold inhibition gain for K417N and K417T, respectively (Friedman test p < 0.0001 for all).
Result: When comparing the inflection temperatures (Ti) of the single RBD mutations with their wt counterpart, we observed a destabilizing
Global Prevalence of Adaptive and Prolonged Infections' Mutations in the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein.
Result: Additionally, mutations K417N, K417T, T470N, T478R, E484A, F490S and Q493K were observed.
Result: All these mutations were observed only in sequences from the USA except for the K417T mutation, which was also found in a sequence from Italy.
Result: During this period, N501Y, L452R and T478K mutations increased by 15.39, 23.06 and 26.75% points, respectively, while E484K, S477N, K417T and S494P mutations decreased by 1.35, 3.09, 0.37 and 0.88% points
Temporal-Geographical Dispersion of SARS-CoV-2 Spike Glycoprotein Variant Lineages and Their Functional Prediction Using in Silico Approach.
Result: Twelve signature amino acid mutations (L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, and V1176F) were observed in the S protein as well as other consensus changes, including ORF1a (S1188L and K1795Q), ORF1b (P214L and E1164D), ORF3a (S253P), PMID: 34722330
2021
Frontiers in cellular and infection microbiology
Introduction: Interestingly, N501Y.V3 (also known as P.1) lineage in Brazil almost has the same three RBD mutations as N501Y.V2 lineage, except for the K417N/T substitution.
Discussion: Indeed, N501Y.V3 lineage includes three mutations in the RBD region (K417T, E484K and N501Y), and it almost has the same three mutations present in RBD as N501Y.V2 lineage, except for K417N/T substitution.
Genomic surveillance reveals the detection of SARS-CoV-2 delta, beta, and gamma VOCs during the third wave in Pakistan.
Introduction: Interestingly, the gamma and beta lineages share three common mutations (K417N/T, E484K, and N501Y) in spike protein.
Introduction: The K417N/T, E484K, and N501Y mutations significantly decreased the neutralizing activity of convalescent and messenger RNA vaccine-induced serum.
Introduction: The gamma variant was first detected in Manaus, Brazil in November, 2020 with the following lineage-defining mutations: E484K, K417T, and N501Y.
Introduction: Among them, the variants P.1 and P.2, first isolated in Brazil possess substitutions of interest in the S protein, including K417T, E484K, N501Y, D614G, and H655Y.
A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants.
PMID: 34732694
2021
Signal transduction and targeted therapy
Result: We investigated several RBD variants within publicly available SARS-CoV-2 sequences in the Global Initiative on Sharing All Influenza Data (GISAID) and all of the individual RBD mutants (N501Y, E484K, E484Q, K417N, K417T, L452R, L452Q, T478K) found in dominant VOCs (B.1.1.7, Alpha; B.1.352, Beta; P.1, Gamma; B.1.617.2, Delta; B.1.427/B.1.429, Epsilon) for n3113.1 binding.
SARS_CoV_2 mutation literature information.
PMID: 
2021
Nature
Browser Board
Co-occurred Entities
Filtrator
ViMRT